CU20170106A7 - Método para obtener alto rendimiento de clones celulares de expresión estable - Google Patents

Método para obtener alto rendimiento de clones celulares de expresión estable

Info

Publication number
CU20170106A7
CU20170106A7 CUP2017000106A CU20170106A CU20170106A7 CU 20170106 A7 CU20170106 A7 CU 20170106A7 CU P2017000106 A CUP2017000106 A CU P2017000106A CU 20170106 A CU20170106 A CU 20170106A CU 20170106 A7 CU20170106 A7 CU 20170106A7
Authority
CU
Cuba
Prior art keywords
protein
grow
recombinant
clones
free media
Prior art date
Application number
CUP2017000106A
Other languages
English (en)
Inventor
Miguel Arias
Xianhong Bai
zhi Bai
Yangliu Cai
Loany Calvo
Maylen Chea
Xiao Chen
Tamara González
Zhenhua He
Yuemao Liu
Julio Palacios
Rolando PÉREZ
Kaiheng Xiao
Zhenhua Yang
Original Assignee
Biotech Pharmaceutical Co Ltd
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotech Pharmaceutical Co Ltd, Ct Inmunologia Molecular filed Critical Biotech Pharmaceutical Co Ltd
Publication of CU20170106A7 publication Critical patent/CU20170106A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>La presente invención se refiere a un método para recuperar clones de células de mieloma recombinante adaptadas para crecer en medios libres de proteínas. Este procedimiento comprende líneas de células de mieloma recombinante para las que el proceso de adaptación de media libre de suero a medio libre de proteína no es posible o toma mucho tiempo y se acompaña de Ia pérdida de producción de anticuerpos debido a Ia aparición de poblaciones de células no productoras. Los procedimientos incluyen un proceso de adaptación gradual para crecer en medio libre de proteínas a baja y alta densidad celular. La adaptación fenotípica para crecer en medio libre de proteínas a alta densidad celular fue acompañada por un aumento en Ia velocidad de secreción de Ia molécula de anticuerpo recombinante y en el porcentaje de clones de células productoras estables. Los clones celulares revelados en Ia presente invención producen el anticuerpo recombinante humanizado Anti - NeuGcGM314F7h. Además, los atributos de identidad de dicho anticuerpo recombinante humanizado anti-NeuGcGM3 14F7 se describen en esta invención.</p>
CUP2017000106A 2015-02-14 2016-03-11 Método para obtener alto rendimiento de clones celulares de expresión estable CU20170106A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510080631.3A CN104651314B (zh) 2015-02-14 2015-02-14 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子
PCT/CN2016/076135 WO2016127954A1 (zh) 2015-02-14 2016-03-11 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子

Publications (1)

Publication Number Publication Date
CU20170106A7 true CU20170106A7 (es) 2018-06-05

Family

ID=53242962

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000106A CU20170106A7 (es) 2015-02-14 2016-03-11 Método para obtener alto rendimiento de clones celulares de expresión estable

Country Status (17)

Country Link
US (1) US10457747B2 (es)
JP (1) JP2018506306A (es)
KR (1) KR20180029948A (es)
CN (1) CN104651314B (es)
AU (1) AU2016218641C1 (es)
BR (1) BR112017017303B8 (es)
CA (1) CA2974027C (es)
CO (1) CO2017008087A2 (es)
CU (1) CU20170106A7 (es)
EA (1) EA201791828A1 (es)
IL (1) IL253932A0 (es)
MX (1) MX2017010421A (es)
MY (1) MY192147A (es)
NZ (1) NZ735485A (es)
SG (1) SG11201706595TA (es)
TN (1) TN2017000302A1 (es)
WO (1) WO2016127954A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104651314B (zh) * 2015-02-14 2018-06-19 百泰生物药业有限公司 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子
EP3257935A4 (en) * 2016-03-11 2018-08-08 Biotech Pharmaceutical Co. Ltd. Method for obtaining high-yield, stable-expression cell clones and antibody molecules obtained thereby
CN113480652B (zh) * 2021-07-30 2023-04-07 成都景泽生物制药有限公司 一种重组cho细胞发酵培养生产重组egfr抗体活性分子的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22731A1 (es) 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
GB0208041D0 (en) * 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
CU23097A1 (es) * 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
AU2004286351A1 (en) * 2003-11-03 2005-05-12 Centocor, Inc. Method for maintaining low shear in a bioprocessing system
CU24120B1 (es) * 2012-03-01 2015-08-27 Ct De Inmunología Molecular Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3
CN104152415B (zh) * 2014-08-13 2015-09-30 百泰生物药业有限公司 获得高产稳定表达重组抗体的骨髓瘤细胞株的方法及应用
CN104651314B (zh) * 2015-02-14 2018-06-19 百泰生物药业有限公司 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子

Also Published As

Publication number Publication date
AU2016218641A1 (en) 2017-10-05
MX2017010421A (es) 2018-04-26
TN2017000302A1 (en) 2019-01-16
CA2974027C (en) 2021-02-16
SG11201706595TA (en) 2017-09-28
BR112017017303B8 (pt) 2024-03-05
US10457747B2 (en) 2019-10-29
AU2016218641C1 (en) 2020-02-27
CA2974027A1 (en) 2016-08-18
BR112017017303B1 (pt) 2023-08-08
NZ735485A (en) 2019-08-30
AU2016218641B2 (en) 2019-10-31
CO2017008087A2 (es) 2017-10-10
US20180016353A1 (en) 2018-01-18
EA201791828A1 (ru) 2017-12-29
MY192147A (en) 2022-08-01
WO2016127954A1 (zh) 2016-08-18
IL253932A0 (en) 2017-10-31
KR20180029948A (ko) 2018-03-21
JP2018506306A (ja) 2018-03-08
CN104651314A (zh) 2015-05-27
CN104651314B (zh) 2018-06-19
BR112017017303A2 (pt) 2018-04-10

Similar Documents

Publication Publication Date Title
AR096839A1 (es) Proceso mejorado para la producción de anticuerpos monoclonales
JP2016104045A5 (es)
PE20191360A1 (es) Metodo para producir anticuerpos multiespecificos
BR112018008648A2 (pt) métodos de geração de células t a partir de células tronco e métodos imunoterapêuticos ao usar células t
CU20190100A7 (es) Anticuerpos biespecíficos y método de fabricación de los mismos
DK1918364T3 (da) Fremgangsmåde til rekloning af produktionsceller
BR112014026308A2 (pt) composições de cultura celular e métodos para produção de polipeptídeos
CU20170106A7 (es) Método para obtener alto rendimiento de clones celulares de expresión estable
BR112015023036A2 (pt) método para preparar um produto alcaloide benzilisoquinolina e célula microbiana engenheirada que produz um produto alcaloide benzilisoquinolina
AR088252A1 (es) Produccion de una proteina de interes mediante un promotor regulable de pichia pastoris
BR112015019341A2 (pt) Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal
MX353144B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
WO2017051347A3 (en) Cells and method of cell culture
EA202091349A1 (ru) Способы культивирования клеток
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
EA201590550A1 (ru) Композиции и способы получения гликопротеинов
BR112018007590A2 (pt) método para produzir proteína de fusão que tem domínio fc de igg
CO6761370A2 (es) Arn interferentespequeños con secuencias seminales con diana especifica
PL439808A1 (pl) Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał
EA202190439A1 (ru) Способ продуцирования cd3-позитивных клеток
MX2021007366A (es) Métodos de clarificación de cultivos celulares.
CO2023018294A2 (es) Métodos de nmr para la comparabilidad de estructuras de orden superior de anticuerpos
TH166463B (th) มีเดียมปราศจาก-ซีรัมที่มี pdgf สำหรับ ds เซลล์
AR119269A1 (es) Métodos y composiciones de cultivo celular para producción de anticuerpos
EA201990837A1 (ru) Антигенсвязывающие белки, характеризующиеся низкой вязкостью, и способы их получения